Making a commitment to equip today’s and future nurses with the knowledge they need to deliver safe, high-quality care, the U.S. Department of Health and Human Services, through the Health Resources and Services Administration, awarded $13 million in October 2022 to programs to improve access to. The awarded funds are part of a series of investments the Biden-Harris Administration earmarked to support pathways to nursing jobs.
Self-reflection is natural as we transition between years, and sometimes doing so can be difficult. Brains seem to really like to hold onto the lows, but give yourself equal time to celebrate the highs you experienced this year and reflect on all you’re grateful for as you get ready for another trip around the sun.
On December 12, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to adagrasib (Krazati®), a RAS GTPase family inhibitor, for adult patients with KRAS G12C–variant locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, and who have received at least one prior systemic therapy.
Significant progress has been made with childhood cancer, especially with the efforts of Children's Oncology Group (COG), but some areas still need attention, Doug Hawkins, MD, COG chair, a National Cancer Institute (NCI)-funded network of researchers and hospitals, explained in a September 2022 interview with NCI.
Inflating more than 50% since 2017, the annual price of newly launched cancer drugs averages $283,000 in 2022, according to a new report from the office of U.S. Representative Katie Porter (D-CA). Although new drugs for any condition are also seeing record-breaking high prices, the cost of new anticancer therapeutics is 3.7 times higher than that of non-oncology drugs.
Patients with cancer experiencing financial hardship during routine care are nearly 1.5 times more likely to die than those who aren’t, researchers reported in study findings published in JCO Oncology Practice.
On December 9, 2022, the U.S. Food and Drug Administration approved atezolizumab (Tecentriq®) for adult and pediatric patients aged 2 years and older with unresectable or metastatic alveolar soft part sarcoma.
The White House Office of Science and Technology Policy updated policy guidance in August 2022 to allow the average American easier access to publications. The new guidance applies to taxpayer-funded research studies and makes the results publicly available for free.
Larry is an 83-year-old rancher who was diagnosed with pancreatic adenocarcinoma and treated with gemcitabine and nab-paclitaxel. A three-month follow-up scan reveals recurrent disease. Larry’s son tells you he wants to explore clinical trials but is frustrated that several promising trials do not accept patients older than 70 years. He asks you why a person’s chronologic age is a major exclusion factor and their performance status is only considered after they meet the age criteria.
The Lymphedema Treatment Act, a key piece of legislation for ONS’s health policy priorities, passed the U.S. House of Representatives in November 2022. The bill is now in the U.S. Senate for review along its journey to becoming law.